Uncategorized
NICE gives qualified nod to Eylea for treatment of diabetic macular edema
The National Institute for Health and Care Excellence has provisionally recommended Eylea as an option for treating diabetic macular edema in preliminary technology appraisal guidance, according to an agency release. Aflibercept (Eylea, Bayer) is recommended when central retinal thickness is 400 µm or more at the start of treatment and when the manufacturer provides aflibercept at an agreed upon discount, according to the agency release.